STEMSYNERGY THERAPEUTICS INC

Search SAM.gov-registered contractors by mission sector, compliance posture and contract vehicle.

Mission sectors

Live demo

Arclight Demo Aerospace & Defense, Inc.

UEI DEMOPRIMEC01 · CAGE 0DEMO · Prime Corporate

CMMC Level 2 (C3PAO)
6 contract vehicles
Case studies & key people
Photo gallery & brand

See the finished profile Download it as an AI-ready Markdown file

A fictional company, built to show every section filled in.

Looking for something specific? Tour the demo profile

Open solicitations, teaming requests and recompetes, from SAM.gov and USAspending.

Pipeline

Popular vehicles

Try an example search

Real filters on live federal data. One click opens the results.

Looking for something specific? Tour the demo profile

AI capture analysis, capability statement grading and plain-language guides.

Analyze

Learn

Ask the AI Capture Analyst

Teaming analysis, best-fit partners, RFP fit and compliance matrices, grounded in TeamingIndex data.

Open the Intelligence Hub Grade a capability statementFree score in seconds. The PDF is never stored.

Looking for something specific? Tour the demo profile

Teaming agreements and proposals, plus how TeamingIndex verifies, protects and connects your data.

Product

Trust

Claim your company, free

Verify your UEI with your work email and control how primes see you. Every badge shows who vouches for it and when.

Claim your profile

Your workspace

Profile, compliance, team, saved searches and billing.

Go to your dashboard

Compare plans

Looking for something specific? Tour the demo profile

See TeamingIndex with real data before you sign up: a finished profile and working searches.

Sample pages

Example searches

Live demo

Arclight Demo Aerospace & Defense, Inc.

UEI DEMOPRIMEC01 · CAGE 0DEMO · Prime Corporate

CMMC Level 2 (C3PAO)
6 contract vehicles
Case studies & key people
Photo gallery & brand

See the finished profile Download it as an AI-ready Markdown file

A fictional company, built to show every section filled in.

Looking for something specific? Tour the demo profile

Popular

See it with data

STEMSYNERGY THERAPEUTICS INC — UEI WVEMHJFUNJ97 | TeamingIndex

Proven teaming graph

Learn more

Who STEMSYNERGY THERAPEUTICS INC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.

See where agencies spend

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more About SBIR/STTR

Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record: 16 awards
Total awarded: $15,246,223
By phase: SBIR Phase I: 9
SBIR Phase II: 6

FedRAMP offerings

Learn more

Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.

Find FedRAMP-authorized companies

Source: FedRAMP Marketplace · sync date not recorded

Exclusions & screening

Exclusions Screening list

Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

GSA CALC+ rate benchmark

Learn more

Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.

See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates · sync date not recorded

Awards (most recent first)

Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,000,000
Sep 22, 2023 – Aug 31, 2025
Solicitation PA22-176 (2022) · Topic 102
Small Molecule N-myc Degraders as Novel Cancer Therapeutic Agents
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $399,999
Apr 5, 2022 – Mar 31, 2023
Solicitation PA21-259 (2021) · Topic NCI
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,976,591
Sep 1, 2021 – Aug 31, 2023
- Direct to Phase II
Solicitation PA20-260 (2020) · Topic NCI
Small Molecule Inhibitors of Notch Activation Complex Kinase (NACK) as Novel Cancer Therapeutic Agents
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $399,999
May 1, 2020 – Apr 30, 2021
Solicitation PA19-272 (2019) · Topic 102
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,997,399
Sep 11, 2019 – Aug 31, 2021
Solicitation PA17-302 (2017) · Topic 102
Development of an Oral WNT inhibitor
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,999
Sep 1, 2018 – Aug 31, 2019
Solicitation PA18-574 (2018) · Topic 102
Development of Notch Pathway Specific Inhibitors as Targeted Therapeutics for Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,994
Aug 1, 2018 – Jul 31, 2019
Solicitation PA17-302 (2017) · Topic 102
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $297,882
Mar 15, 2018 – Feb 28, 2019
Solicitation PA17-302 (2017) · Topic 102
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $2,999,979
Sep 1, 2017 – Aug 31, 2020
Solicitation CA16-008 (2016) · Topic 102
Development of a WNT Inhibitor for Regenerative Healing of Burn Injuries
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $225,000
Sep 16, 2016 – Aug 31, 2018
Solicitation PA15-269 (2015) · Topic 300
Development of a LRP6 Monoclonal Antibody for Triple Negative Breast Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,968
Sep 5, 2016 – Aug 31, 2018
Solicitation PA15-269 (2015) · Topic 102
Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,991
Mar 1, 2015 – Feb 28, 2017
Solicitation PA14-072 (2015) · Topic 102
Development of a WNT Inhibitor for Advanced Stage Lung Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,499,974
Sep 16, 2014 – Aug 31, 2016
Solicitation PA13-234 (2014) · Topic 102
Targeting stem cell populations in lung cancer by modulating the Wnt and p53 path
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $259,451
Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub
Development of Wnt Pathway Inhibitors for Colorectal Cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2012 · $1,999,997
Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub
Development of Wnt Pathway Inhibitors for Colorectal Cancer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $140,000
Solicitation PHS2010-2 (2010) · Topic NCI

Compliance posture: unverified (SAM.gov baseline only)

About STEMSYNERGY THERAPEUTICS INC

Identifiers

Ready to team with STEMSYNERGY THERAPEUTICS INC?

Capabilities & differentiators

Compliance posture

Facility clearance

Past performance

Contract vehicles

Proven teaming graph

SBIR/STTR portfolio

FedRAMP offerings

Exclusions & screening

SAM.gov exclusions

GSA CALC+ rate benchmark

NAICS, PSC & socio-economic status

Teaming preferences

Business development contact

Corporate hierarchy

Data sources & provenance

Consolidated Screening List